Traditional mechanisms thought to underlie opioid tolerance include receptor phosphorylation͞down-regulation, G-protein uncoupling, and adenylyl cyclase superactivation. A parallel line of investigation also indicates that opioid tolerance development results from a switch from predominantly opioid receptor Gi␣ inhibitory to G␤␥ stimulatory signaling. As described previously, this results, in part, from the increased relative abundance of G ␤␥-stimulated tolerance ͉ dependence ͉ opioid ͉ phosphorylation ͉ protein kinases A and C
R
esponsiveness to opioids includes initial perturbations that are followed by the reestablishment of ''normal'' physiological equilibrium despite its continued presence. Despite the delineation of many of the physiological, biochemical, and molecular biological sequela of persistent exposure to opioids, elucidation of the cellular events that are causally associated with the reestablishment of homeostasis following chronic morphine remains incomplete. There is now growing evidence that although traditional explanations for opioid tolerance (e.g., receptor down-regulation, desensitization, G-protein uncoupling) do contribute, these mechanisms are not the exclusive underpinnings of opioid tolerance (see ref. 1 for review).
Opioid receptors are predominantly coupled to adenylyl cyclase (AC) via the G i␣ subunit of G proteins. Previous reports, however, have underscored the relevance of enhanced opioid receptor signaling via G ␤␥ to the biochemical underpinnings of opioid tolerance. In the ileum longitudinal muscle myenteric plexus preparation (LMMP), chronic in vivo morphine treatment results in augmented levels of mRNA encoding AC IV (2) and VII (S.C., L. Wang, and A.R.G., unpublished observations), both of which are stimulated by G ␤␥ (3) . In the LMMP tissue, persistent in vivo activation of opioid receptors also induces a profound increase in AC (type II family) phosphorylation (4) that can significantly increase their stimulatory responsiveness to G ␤␥ (as well as G s␣ ) (5) (6) (7) . These changes contribute to enhanced G ␤␥ stimulatory AC signaling that occurs following chronic morphine treatment (8) and thus underlie the altered opioid regulation of transmitter release (9) and cAMP formation (10, 11) in these preparations.
In addition to AC, G ␤␥ also interacts with other cell-signaling proteins, one group of which is G protein-coupled receptor kinase (GRK) 2͞3 (12) . These are cytosolic serine͞threonine kinases that participate in homologous G protein-coupled receptor (GPCR) desensitization via their phosphorylation upon agonist binding. Translocation, membrane attachment, and subsequent activation of GRK2͞3 require the G ␤␥ subunit of heterotrimeric G protein (13) . Thus, the formation of GRK͞G ␤␥ complexes is critical to desensitization of cellular signaling mediated via GPCRs (14) .
The formation of GRK͞G ␤␥ complexes also has significant functional implications regarding the increased role of G ␤␥ signaling in opioid tolerance. The carboxyl third of GRK2͞3, the region that contains the G ␤␥ binding sequences, can inhibit G ␤␥ stimulation of AC II (15) , and presumably the other ACs of the type II family (AC IV and VII) as well as other effectors known to be regulated by G ␤␥ (16) . Thus, changes in the dynamics of GRK͞G ␤␥ interactions could be critical to increased chronic morphine-induced opioid receptor-coupled G ␤␥ stimulatory AC signaling (4, 8) as well as changes in other G ␤␥ -sensitive signaling cascades (e.g., phospholipid metabolism, mitogen-activated protein kinase) that have been associated with opioid tolerance͞dependence (17) .
We find that chronic morphine augments the concomitant phosphorylation of GRK2͞3, ␤-arrestin, and G ␤ . These proteins are coimmunoprecipitated by using two distinct, highly selective antisera. Phosphorylation has opposing consequences on their association; as a result, availability of G ␤␥ is increased without compromising the membrane content of GRK2͞3. Opioid-induced concomitant phosphorylation of several proteins in a multimolecular complex with attendant modulation of their association represents a novel mechanism for increasing G ␤␥ signaling and opioid tolerance formation.
Materials and Methods
Materials. Morphine pellets were supplied by the National Institute on Drug Abuse. 32 P-labeled inorganic phosphorus ( 32 Pi) was obtained from New England Nuclear. All protein kinase and phosphatase inhibitors were purchased from Alexis (San Diego, CA). All protease inhibitors were purchased from Sigma, except for complete protease inhibitor mixture, which was purchased from Roche Molecular Biochemicals. Anti-␤-arrestin2 antibodies, recombinant GRK2 protein, and transformed Escherichia coli containing the expression plasmid pGEX͞␤-arrestin-CT were generously supplied by R. J. Lefkowitz (Duke University, Durham, NC). Anti-G ␤ antibodies and purified G ␤␥ dimer were generously supplied by J. Hildebrandt (Medical University of South Carolina, Charleston, SC). Anti--opioid receptor antibody was generously provided by Robert Elde (University of Minnesota, Minneapolis, MN). 32 Pi. Studies were carried out in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National Institutes of Health. Morphine tolerance͞dependence was induced by s.c. implantation of five morphine pellets (each containing 75 mg morphine base) into male albino guinea pigs (375-450 g) under light anesthesia. On the 6th day following pellet implantation, animals were killed, and ilea were removed and washed with phosphate-free Krebs buffer (pH 7.5). Myenteric plexus and attached longitudinal muscle (LMMP) were removed and equilibrated in the same buffer with continuous gassing (95% O 2 , 5% CO 2 ) at 35°C for 30 min (11). For tolerant͞dependent LMMP tissue, morphine (100 nM) was included in the buffer. LMMP strips were then incubated with 1 mCi͞ml (1 Ci ϭ 37 GBq) 32 Pi in phosphate-free Krebs (2 h at 35°C) with continuous gassing. To determine the effect of acute opioid treatment on protein phosphorylation, opioid naïve LMMP strips were incubated with morphine (100 nM) during the last 5 min of 32 Pi incubation. The kinase(s) required for chronic morphine-induced augmented phosphorylation was inferred from the effect of inhibitors on the incorporation of 32 P into protein in LMMP tissue obtained from morphine-treated animals. LMMP tissue from the same ileum was randomly divided into two samples, one of which contained a kinase inhibitor that was able to discriminate between protein kinase C (PKC) or protein kinase A (PKA). Inhibitors were added during the last 30 min of the 2-h 32 P labeling period. Chelerythrine and calphostin C were used as PKC-selective inhibitors; HA-1004 and H-89 were used as PKA-selective inhibitors. Inhibitor concentrations were selected to maximize discrimination between PKC and PKA as well as inhibition of the targeted kinase.
LMMP Preparation and Incubation with
Following incubation with 32 Pi, LMMP tissues were washed extensively with phosphate-free Krebs buffer and homogenized in Tris buffer (10 mM, pH 7.6) containing 10% sucrose͞2 mM DTT͞5 mM EDTA͞1 mM EGTA͞10 mM sodium pyrophosphate͞protease inhibitors (100 g͞liter bacitracin; 20 g͞liter each of chloromethyl ketone, N ␣ -p-tosyl-L-lysine chloromethyl ketone, and PMSF; 3.2 g͞liter each of leupeptin and soybean trypsin inhibitor; 0.5 g͞liter aprotinin, 1 mM benzamidine and complete inhibitor mixture, one tablet͞50 ml)͞protein phosphatase inhibitors (25 nM calyculin A, 1 M okadaic acid, 100 M sodium orthovanadate). Supernatant obtained from a low-speed centrifugation (1,000 ϫ g, 4°C, 10 min) was subjected to a high-speed centrifugation (30,000 ϫ g, 4°C, 30 min). Membranes obtained were resuspended in 50 mM Tris buffer containing 1 mM DTT, 10 mM sodium pyrophosphate and the above-mentioned protease and phosphatase inhibitors.
Immunoprecipitation of GRK2͞3, ␤-Arrestin, and G␤ Protein. Immunoprecipitation of specific proteins used a mouse monoclonal antibody generated against rat GRK2͞3 (last 221 C-terminal residues) (18) or polyclonal antibodies generated against a glutathione S-transferase fusion protein encoding the last 75 residues (336-411) of the carboxyl terminus of rat ␤-arrestin2 (19) or the C-terminal last 11 aa residues of G ␤ (20) . Membranes were solubilized in buffer containing phosphatase and protease inhibitors, as described above, containing 1% Nonidet P-40͞0.5% sodium deoxycholate͞0.1% SDS͞5% glycerol͞150 mM NaCl (60 min on ice), vortexed three times, and centrifuged (14,000 ϫ g for 30 min). Protein amounts were determined by the Bradford method (21) by using BSA as a standard. Solubilized membrane protein (1.4 mg) from each sample was incubated with either 24 g of anti-GRK2͞3 antibodies or a 1:200 dilution of anti-␤-arrestin or G ␤ antibodies (each for 60 min at 4°C). Immunoprecipitation and SDS͞PAGE (10%) were performed as previously described (4) . A prestained protein ladder (10-200 kDa, Life Technologies, Grand Island, NY) was included in each electrophoresis to control for variation in running time and͞or subtle differences in gel composition, running temperature, etc. among experiments. Molecular mass of the proteins being monitored, calculated by extrapolation from the mobility of molecular mass standards that were included with each run, were very comparable among all experiments. Gels were dried and exposed to PhosphorImager screens that were scanned in a PhosphorImager Storm 860 (Molecular Dynamics). Amounts of 32 P incorporated into the phosphorylated protein bands were determined by using densitometric analysis (Imagequant, Molecular Dynamics).
Gel Electrophoresis and Western Blot Analysis. Standard procedures were used for Western analyses as used previously by this laboratory (8) . Selected lanes from polyacrylamide gels were incubated (room temperature for 2 h) with either a mouse monoclonal antibody generated against GRK2͞3 (C5͞1, 4 g͞ml) or polyclonal antibodies generated against G ␤ or ␤-arrestin͞preadsorbed anti-␤-arrestin antisera (each dissolved in blocking solution, 1:1,000). The secondary antibody used was either a peroxidase-labeled antimouse (for GRK2͞3) or anti-rabbit (for ␤-arrestin) antibody. Antibody-substrate complex was visualized by using an enhanced chemiluminescence detection kit (Amersham Pharmacia). Sample pairs, obtained from opioid naïve and chronic morphine-treated LMMP tissues, were processed, electrophoresed, and blotted in parallel, after which they were exposed concomitantly to the same Kodak X-Omat film (New England Nuclear). Signal intensity was quantified by using National Institutes of Health imaging software.
Preparation of Preadsorbed Anti-␤-Arrestin Antibodies. Transformed E. coli containing the expression plasmid pGEX͞␤-arrestin-CT was grown in a large scale in LB͞ampicillin media. Following induction of the cultures with 1 mM isopropyl-1-thio-␤-D-galactopyranoside (37°C, 3 h), cells were harvested by centrifugation (5,000 ϫ g for 10 min). Cells were lysed in PBS containing protease inhibitors (0.1 mM PMSF͞0.31 mg/ml benzamidine͞4 g/ml leupeptin͞5 g/ml aprotinin͞1 g/ml pepstatin A) by repeated freeze-thawing, which was followed by sonication and centrifugation (10,000 ϫ g for 10 min; 4°C). glutathione S-transferase-␤ arrestin2-CT fusion protein from the supernatant was immobilized on glutathione-Sepharose (Amersham Pharmacia), on which diluted (1:1) anti-␤-arrestin antibodies were adsorbed. The void volume was collected and concentrated such that the dilution of preadsorbed and nonadsorbed antiserum was the same.
Purification of G␤␥ Subunits and in Vitro Phosphorylation of Purified
G␤␥. G ␤␥ subunits were purified from bovine brain by a modification of procedures originally described for the isolation and purification of G protein after heterotrimer activation (22) . Briefly, G protein was extracted from bovine brain membranes with 1% sodium cholate and separated from other proteins by DEAE chromatography, followed by AcA34͞Octyl-agarose chromatography and Mono-Q FPLC.
Phosphorylation of purified G ␤␥ (10 g) was carried out (30 min at 30°C) in a final volume of a 0.1-ml reaction mixture containing 20 mM Tris, pH 7.6͞10 mM MgCl 2 ͞1.0 mM CaCl 2 ͞0.25% BSA͞1.0 mM DTT͞40 g/ml leupeptin͞40 M PMSF͞phospha-tase inhibitors (0.1 mM sodium vanadate, 1 M okadaic acid, 25 nM calyculin A, 100 M ATP). The reaction was initiated by addition of PKA (150 U) and͞or PKC (18 mU) catalytic subunits (as recommended by the manufacturer, Calbiochem) or an equivalent volume (20 l) of water. Following phosphorylation, the reaction mixture was incubated with purified recombinant GRK2 protein (18 g per reaction; 1 h at 5°C), after which immunoprecipitation by using anti-G ␤ antibodies and Western analysis by using anti-GRK2͞3 antibodies commenced as described above. In separate, parallel experiments, the stoichiometry of 32 P incorporation into G ␤ subunit was determined under identical conditions by incubating the purified protein with [␥- Statistical Analysis. Significance of autoradiographic and Western analyses was assessed by using 2-tailed Student's t test. Percent inhibition of phosphorylation by kinase inhibitors was evaluated by using a one-tailed t test.
Results
Coimmunoprecipitation of Phosphorylated GRK2͞3, ␤-Arrestin, and G␤. Immunoprecipitate of 32 P-radiolabeled LMMP tissue obtained from opioid naïve and chronic morphine-treated tissue by using either anti-G ␤ or anti-GRK2͞3 antibodies (G ␤ immunoprecipitate, GRK2͞3 immunoprecipitate, respectively) contained predominantly three phosphorylated proteins of Ϸ80, 45, and 33 kDa (Fig.  1) . Preincubation of anti-G ␤ antibodies with a 10-fold excess of purified bovine G ␤␥ protein before immunoprecipitation markedly reduced (Ͼ90%) the radiolabel intensity of the Ϸ33-kDa band consistent with its G ␤ identity (Fig. 1 A, lane 3) . Similarly, preincubation of anti-GRK2͞3 antibodies with a 10-fold excess of synthetic peptide corresponding to (Asn-478-Glu-491 of bovine GRK2͞3), which was recognized by anti-GRK2͞3 antibodies in ELISA assays (Martin Oppermann, personal communication), markedly reduced (Ͼ90%) the radiolabel intensity of the Ϸ80-kDa band consistent with its GRK2͞3 identity (Fig. 1B, lane 3) . Consistency of calculated molecular mass of autoradiographic signals and those obtained in Western analysis of purified protein and GRK͞G ␤ immunoprecipitate further confirms that the phosphorylated Ϸ80-, Ϸ45-, and Ϸ33-kDa phosphorylated bands are GRK2͞3, ␤-arrestin, and G ␤ , respectively (data shown in lane 4 of Fig 1 panels) . The presence of all three proteins in immunoprecipitate obtained by using anti-GRK2͞3 or G ␤ antibodies combined with their absence in immunoprecipitate obtained with preadsorbed antiserum indicates that they are present in a multimolecular complex.
In contrast to G ␤ and GRK2͞3, immunoprecipitate that was obtained with anti-␤-arrestin antibodies did not contain phosphorylated bands of Ϸ80 or Ϸ33 kDa ( Fig. 2A) . ␤-arrestin immunoprecipitate only contained one phosphorylated band, the molecular mass of which (Ϸ45 kDa; Fig. 2 A) is identical to that of the intermediate size band observed in the autoradiogram of both G ␤ and GRK2͞3 immunoprecipitate (Fig. 1) . It is also identical to the signal observed in Western analysis of GRK2͞3 immunoprecipitate (Fig. 1B, lane 4b) and LMMP membranes (Fig. 2B ) using anti-␤-arrestin antibodies. The Ϸ45-kDa signal was no longer detected in Western analysis by using preadsorbed ␤-arrestin antiserum (Fig.  2B, lane 3) .
Effect of Chronic Morphine on 32 P Incorporation into GRK2͞3, ␤-
Arrestin, and G ␤ Proteins. Chronic morphine altered the phosphorylation state of GRK2͞3, ␤-arrestin, and G ␤ , but the nature and Fig. 1 . Effect of chronic morphine on phosphorylation of proteins immunoprecipitated using anti-G ␤ (A) or anti-GRK2͞3 (B) antibodies. LMMP tissue obtained from opioid naïve (lane 1) and chronic morphine-treated (lane 2) guinea pigs was incubated with 32 P for 2 h. Membranes were prepared, solubilized, and immunoprecipitated using antibodies selective for either G ␤ (A) or GRK2͞3 (B). In lane 3 of both panels, preadsorbed antiserum was used for immunoprecipitation of LMMP tissue obtained from chronic morphine-treated animals. Immunoprecipitates were subjected to SDS͞PAGE, and radiolabeled proteins were visualized by their concomitant autoradiography (18-h exposure) using storage phosphorimaging techniques. Quantitative densitometric analysis was used to assess magnitude of 32 All procedures were performed as described in Materials and Methods. The ␤-arrestin antibody used was generated against the 75-aa C-terminal domain of ␤-arrestin2 (Ϸ80% homologous to the corresponding region of ␤-arrestin1). Furthermore, because this antiserum was polyclonal, it would undoubtedly contain antibody generated against multiple epitopes. It is thus highly unlikely that it differentiates between ␤-arrestin1 and -2 when used for immunoprecipitation vs. Western analyses.
magnitude of the change that was observed depended on the antibody used for immunoprecipitation. Chronic morphine augmented phosphorylation of the GRK2͞3, ␤-arrestin, and G ␤ that was present in immunoprecipitate obtained using either anti-G ␤ or GRK2͞3 antibodies, but this phosphorylation increment was greater in the anti-G ␤ immunoprecipitate. In G ␤ immunoprecipitate, chronic morphine increased incorporation of 32 P into GRK2͞3, ␤-arrestin, and G ␤ by 194 Ϯ 16.4%, 115 Ϯ 28.6%, and 199.5 Ϯ 27%, respectively ( Fig. 1 A, compare lanes 1 and 2; n ϭ 4, P Ͻ 0.05). However, the phosphorylation increment of GRK2͞3, ␤-arrestin, and G ␤ observed in immunoprecipitate obtained using anti-GRK2͞3 antibodies was only 44 Ϯ 7.6%, 74.3 Ϯ 19%, and 76.5 Ϯ 25%, respectively (Fig. 1B, compare lanes 1 and 2 ; n ϭ 5, P Ͻ 0.05). Although chronic morphine increased phosphorylation of ␤-arrestin that was coimmunoprecipitated with anti-GRK2͞3 or G ␤ antibodies, this treatment decreased (43 Ϯ 7.1%; n ϭ 3, P Ͻ 0.05) phosphorylation of (free) ␤-arrestin that was immunoprecipitated with anti-␤-arrestin antibody (Fig. 2 A, compare lanes 1  and 2) .
In contrast to observations made in tolerant͞dependent tissue, increased 32 P incorporation into proteins of Ϸ80, Ϸ45, and Ϸ33 kDa was not observed following acute in vitro morphine treatment of opioid naïve tissue (100 nM during the last 5 min of 32 Pi incubation; n ϭ 2; data not shown). These parameters of morphine exposure are sufficient to produce a Ͼ50% reduction of the electrically induced LMMP contracture (23) . The augmented phosphorylation of these proteins following chronic but not acute exposure to morphine suggests its relevance to mechanisms underlying tolerance.
Chronic Morphine Does Not Alter the LMMP Membrane Content of ␤-Arrestin or GRK2͞3 but Reduces the Content of GRK2͞3 in G␤
Immunoprecipitates. Western analyses of LMMP membranes reveal that chronic morphine does not alter their content of ␤-arrestin (Fig. 2B, lanes 1 and 2) or GRK2͞3 (Fig. 3A) . This laboratory previously reported analogous findings for the LMMP membrane content of G ␤ (8). Thus, their altered phosphorylation following chronic morphine results from the ability of this treatment to change the equilibrium between phosphorylated and nonphosphorylated forms.
Western analysis of G ␤ immunoprecipitates using anti-GRK2͞3 antibodies indicates that chronic morphine reduces the total amount of GRK2͞3 (phosphorylated and nonphosphorylated) that coimmunoprecipitates with G ␤ (Ϸ40%, n ϭ 4, P Ͻ 0.05; Fig. 3B ). This notwithstanding, the phosphorylation of the GRK that is present in G ␤ immunoprecipitate obtained from chronic morphinetreated LMMP tissue is increased Ϸ2-fold. Thus, this augmented phosphorylation is manifested by a reduced pool of protein indicating its enhanced interaction with G ␤ . The preferential binding of phosphorylated GRK2͞3 to G ␤ is consistent with reports of its increased membrane translocation following phosphorylation by PKC (24) . It should be noted that, consistent with quantitative Western analysis of LMMP membrane G ␤ , equivalent amounts of G ␤ protein were present in G ␤ immunoprecipitate obtained from opioid naïve vs. chronic morphine-treated LMMP tissue (Fig. 3C,  lanes 1 and 2) . Consequently, G ␤ phosphorylation, augmented in LMMP tissue following chronic morphine, does not alter antibody recognition of this protein, immobilized or in solution. Thus, it does not confound interpretation of the reduced presence of GRK2͞3 in G ␤ immunoprecipitate following chronic morphine.
The reduced content of GRK2͞3 in G ␤ immunoprecipitate obtained from chronic morphine-treated tissue in combination with the augmented phosphorylation of G ␤ in these preparations suggests that phosphorylation of G ␤ reduces its ability to associate with GRK2͞3. To validate this inference, we performed in vitro phosphorylation experiments that assessed the effect of purified bovine G ␤␥ phosphorylation on its association with purified recombinant GRK2. Studies with inhibitors of PKA and PKC indicate that the activity of both contributes to the observed chronic morphineinduced increased phosphorylation of monitored proteins (see below). To simulate this in vitro, both kinases and purified G ␤␥ were used. The stoichiometry of phosphorylation was 0.45 Ϯ 0.01 mol of phosphate incorporated͞mol of G ␤ subunit (n ϭ 3). In vitro phosphorylation of G ␤ (Fig. 4A ) attenuated its association with recombinant GRK2. This was indicated by quantitative analysis of Western blots in which G ␤ immunoprecipitate contained Ϸ50% less GRK2 when this protein was incubated with phosphorylated vs. nonphosphorylated G ␤␥ protein, respectively (n ϭ 2; Fig. 4B ). When purified G ␤ protein was phosphorylated with the catalytic subunit of either PKA or PKC, individually, G ␤ immunoprecipitate contained Ϸ33% less GRK2 (n ϭ 2), indicating the summation of their effects. The kinase inhibitors used in this study were selected on the basis of their relative selectivity for PKC vs. PKA. Concentrations were selected to maximize selectivity and inhibition of the targeted kinase. Attenuation (Ϸ50-80%), but not abolishment, of chronic morphine-induced phosphorylation of the Ϸ80-, Ϸ45-, and Ϸ33-kDa bands was observed following a 30-min treatment with all inhibitors used (Fig. 5) . In contrast, concomitant incubation with chelerythrine and H-89 abolished chronic morphine-induced 32 
P incorporation into immunoprecipitated proteins (data not shown).

Discussion
This laboratory previously demonstrated that chronic morphine augments opioid receptor-coupled G ␤␥ stimulatory AC signaling. This was shown to result, at least in part, from the increased synthesis of ACs of the type two family (2, 8) as well as a profound increase in their phosphorylation state (4) . The present study demonstrates that chronic treatment with morphine also results in the concomitant phosphorylation of GRK2͞3, ␤-arrestin, and G ␤ , the identities of which were unambiguously identified by using targeted immunoprecipitation in combination with Western analysis of (i) purified protein, (ii) immunoprecipitates, and (iii) LMMP membranes. All three proteins are coimmunoprecipitated using anti-GRK2͞3 or G ␤ . Phosphorylation alters the association of these signaling molecules, one consequence of which would be to maximize the availability of G ␤␥ for interaction with AC and other effectors.
The magnitude of the augmented phosphorylation that is observed as a function of chronic morphine treatment was found to vary with the antibody used to immunoprecipitate proteins. However, chronic morphine-induced phosphorylation increments of monitored protein was always determined by using the same antibody to process, in parallel, opioid naïve vs. chronic morphinetreated LMMP tissue. Therefore, interpretation of antibodydependent differences (see below) should not be influenced by variations in immunoprecipitation efficiency among the antibodies.
Chronic morphine-induced phosphorylation of GRK2͞3 seems to alter its association with G ␤ . This conclusion is based on the fact that the GRK2͞3 immunoprecipitate should contain predominantly (albeit not exclusively) free GRK2͞3 in contrast to the exclusive presence of complexed GRK2͞3 in immunoprecipitate obtained using anti-G ␤ antibody. The smaller chronic morphineinduced increment in phosphorylation of GRK2͞3 that is present in GRK2͞3 vs. G ␤ immunoprecipitate (Ϸ44% vs. Ϸ194%, respectively) implies that phosphorylation of GRK2͞3 increases its association with G ␤␥ , consistent with the increased translocation of phosphorylated GRK to the membrane (24).
Chronic morphine-induced phosphorylation of ␤-arrestin produces an analogous effect. Autoradiography of ␤-arrestin immunoprecipitate reveals only a single phosphorylated band (Ϸ45 kDa); there is no detectable presence of either phosphorylated GRK2͞3 or G ␤ . This would be expected because the C-terminal antibody recognition site (19) is the region known to bind to phosphorylated GPCRs (25) . The decrease (Ϸ43%) in ␤-arrestin phosphorylation manifested in ␤-arrestin immunoprecipitate vs. the increased phosphorylation (Ϸ115%) of the ␤-arrestin that coimmunoprecipitates with G ␤ suggests that its chronic morphine-induced phosphorylation promotes association with G ␤␥ .
In contrast, phosphorylation of G ␤ seems to attenuate its association with GRK2͞3. This is indicated by (i) the significantly smaller chronic morphine-induced G ␤ phosphorylation increment manifested in GRK2͞3 vs. G ␤ immunoprecipitate; (ii) chronic morphine-induced augmented phosphorylation of G ␤ is associated with decreased coimmunoprecipitation of GRK2͞3 protein (Fig.  3B) ; and (iii) in vitro phosphorylation of purified bovine G ␤␥ via PKC and PKA, both of which contribute to its chronic morphineinduced phosphorylation in vivo, attenuates its interaction with recombinant GRK2 protein (Fig. 4) . Because equivalent amounts of G ␤ protein are contained in anti-G ␤ immunoprecipitate derived from opioid naïve vs. chronic morphine-treated preparations (Fig.  3C ), data interpretation is not confounded by differential immunoprecipitation of nonphosphorylated vs. phosphorylated G ␤ .
The consequences of chronic morphine-induced augmented phosphorylation of G ␤ and GRK2͞3 have substantial functional implications regarding altered opioid receptor-coupled signaling that result from persistent opioid receptor activation. Decreased association of G ␤␥ with GRK2͞3 would increase its availability for interaction with biological effectors such as AC. This could contribute to the augmented G ␤␥ stimulatory AC signaling demonstrated in chronic morphine-treated LMMP tissue (8) . Additionally (or alternatively), the phosphorylated G ␤ subunit could participate in an enzymatic transfer of a phosphate to GDP at G protein ␣ subunits (26) and thereby prevent reformation of heterotrimeric G proteins. This would maintain the pool of free G ␤␥ subunits available for signaling. Therefore, increased signaling via G ␤␥ subunits during opioid tolerance could result not only from effector modification (AC isoform-specific synthesis and phosphorylation) but from chemical modification (phosphorylation) of signaling͞transducing molecules as well.
Phosphorylation of GRK2͞3 has previously been shown to increase its kinase activity (27, 28) . Additionally, it promotes association with G ␤␥ (as described herein). Thus, the effect of chronic morphine treatment on the interaction between GRK and G ␤ is the result of two competing processes. Phosphorylation of GRK increases whereas phosphorylation of G ␤ decreases their interaction. However, the effect of increasing levels of phosphorylated G ␤ on complex formation predominates. This is evidenced by the observation that in chronic morphine-treated tissue, the total amount of GRK that coimmunoprecipitates with G ␤ is significantly reduced (Fig. 3B) . Thus, following chronic morphine, the net effect is a reduction in the association between GRK and G ␤ . Nevertheless, the membrane content of GRK remains constant. The most plausible explanation is that phosphorylation of G ␤ effectively reduces the amount of this protein that would be available for interaction with GRK, which is partially compensated for by the enhanced ability of phosphorylated GRK to interact with nonphosphorylated G ␤ . Following chronic morphine, G ␤␥ continues to recruit GRK2͞3 to the membrane that is then stored in association with charged membrane phospholipids via a pleckstrin homology domain (29) . Such interactions are known to be essential for agonist-dependent phosphorylation of GPCRs by GRK2͞3 (30) .
The coimmunoprecipitation of phosphorylated GRK2͞3, ␤-arrestin, and G ␤ , using antibodies generated against either GRK2͞3 or G ␤ but not preadsorbed antiserum, indicates that all three proteins exist in the membrane, at least in part, as a multi- PKA inhibit the chronic morphineinduced phosphorylation of GRK2͞3, ␤-arrestin, and G␤. LMMP tissue from the same chronic morphine-treated guinea pig was randomly divided such that 32 P incorporation into G ␤-immunoprecipitated protein could be concomitantly determined in the absence as well as presence of kinase inhibitors (added during the last 30 min of the 2-h 32 P labeling period). Membranes were prepared and solubilized, and proteins were immunoprecipitated using anti-G ␤ antibodies.
Immunoprecipitates were subjected to electrophoresis, and radiolabeled proteins were visualized by their concomitant autoradiography (18-h exposure) using storage phosphorimaging techniques. Quantitative densitometric analysis was used to assess magnitude of 32 P incorporation into Ϸ80-, 45-, and 33-kDa signals. Chemical identity of each was assessed as described in Fig. 1 . Data are expressed as a percent inhibition of the 32 P incorporation observed in the absence of kinase inhibitors. n ϭ 4, 3, 3, and 2 for chelerythrine, calphostin C, H-89, and HA1004, respectively. All reductions in phosphorylation are significant (P Ͻ 0.05). molecular complex. This is consistent with previous demonstrations of interactions between GRK2͞3 and G ␤␥ (12, 31) . It is also consistent with (i) the ability of ␤-arrestins to bind to phosphorylated GPCR (32), (ii) the extensive colocalization of the ␤ 2 -adrenergic receptor and GRK2͞3 in intracellular vesicles following receptor stimulation (33) , and (iii) the formation of a GRK2͞␤-arrestin͞CCR2 receptor complex upon receptor activation (34) . The present results demonstrate the existence of steady-state levels of a complex simultaneously consisting of ␤-arrestin, GRK2͞3, and G ␤␥ . The presence of the -opioid receptor in GRK2͞3 immunoprecipitate, detected by Western analysis using an anti--opioid receptor antibody (ref. 35 and data not shown) could explain, at least in part, the coimmunoprecipitation of ␤-arrestin with GRK and G ␤ proteins.
GRK2͞3 have been shown to be subject to phosphorylation and regulation by multiple kinases. c-Src can directly phosphorylate GRK2 on tyrosine residues (28) . Additionally, a mixture of PKCs, purified from rat brain, phosphorylates purified recombinant ␤-adrenergic receptor kinase-1 (␤ARK-1) (24). The current observations that chronic morphine-induced phosphorylation of GRK2͞3 in LMMP tissues, as well as ␤-arrestin and G ␤ , was significantly reduced (50-80%), but not abolished, by kinase inhibitors at concentrations that enable discrimination between PKC and PKA underscores that the activities of both are required for their chronic morphine-induced phosphorylation. Involvement of PKC in the chronic morphine-induced AC phosphorylation in the LMMP tissue as well as the shift from predominantly opioid receptor inhibitory to stimulatory signaling has previously been reported (4, 36) . The imputed role of PKC in opioid tolerance in LMMP tissue is consonant with its up-regulation in this tissue (36) as well as in spinal cord following chronic morphine treatment (37) . The current demonstration of the involvement of PKA is consistent with the important role this kinase family plays in other biochemical sequelae of chronic morphine (38) and its up-regulation following chronic opioid administration (39) .
In summary, chronic systemic administration of morphine was found to augment the concomitant phosphorylation of key signaling proteins. Targeted immunoprecipitation resulted in the coimmunoprecipitation of GRK2͞3, ␤-arrestin, and G ␤ . Antibody selectivity in combination with the observed antibody-dependent increment in phosphorylation indicates that phosphorylation of GRK2͞3, ␤-arrestin, and G ␤ alters their association. As a result, there would be increased availability of G ␤␥ while maintaining constant membrane levels of GRK.
G ␤␥ subunits, derived from heterotrimeric G proteins upon activation of GPCRs, play a complex role in signal transduction (16) . Potassium channels as well as many signal transduction enzymes, e.g., phospholipase A 2 , phospholipase C␤, AC isoforms, mitogen-activated protein kinase, are regulated by G ␤␥ (16, 40) . The nature of the regulation can be quite complex depending both on the effector and on interactions with G ␣ subunits. Decreased association of G ␤␥ subunits with GRK2͞3 and its consequent increased availability to interact with other signaling proteins could result in the altered activity of divergent signaling cascades and thus have functional implications that are quite broad. This could underlie, in part, the multiplicity of systems that are affected by chronic morphine and the resulting complexity of opioid tolerance and dependence.
